Ewa Ellis

Ewa Ellis

Auto-generated profile, based on publicly available information

Ewa Ellis

Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Cell
Verified
Journal Article
Open access
MHMeritxell Huch
Meritxell Huch
HGHelmuth Gehart
Helmuth Gehart
RBRuben van Boxtel
Ruben van Boxtel
KHKarien Hamer
Karien Hamer
FBFrancis Blokzijl
Francis Blokzijl
Hans CleversHans Clevers
Hans Clevers
Despite the enormous replication potential of the human liver, there are currently no culture systems available that sustain hepatocyte replication and/or function in vitro. We have shown previously that single mouse Lgr5+ liver stem cells can be expanded as epithelial organoids in vitro and can be differentiated into functional hepatocytes in vitro and in vivo. We now describe conditions allowing long-term expansion of adult bile duct-derived bipotent progenitor cells from human liver. The expanded cells are highly stable at the chromosome and structural level, while single base changes occur at very low rates. The cells can readily be converted into functional hepatocytes in vitro and upon transplantation in vivo. Organoids from α1-antitrypsin deficiency and Alagille syndrome patients mirror the in vivo pathology. Clonal long-term expansion of primary adult liver stem cells opens up experimental avenues for disease modeling, toxicology studies, regenerative medicine, and gene therapy.

29 July 2007 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
HAHisaya Azuma
Hisaya Azuma
NPNicole Paulk
Nicole Paulk
ARAarati Ranade
Aarati Ranade
CDCraig Dorrell
Craig Dorrell
MAMuhsen Al-Dhalimy
Muhsen Al-Dhalimy
MGMarkus Grompe
Markus Grompe

4 May 2016 in Scientific Reports
Verified
Journal Article
Open access
CBCatherine C. Bell
Catherine C. Bell
DHDelilah F. G. Hendriks
Delilah F. G. Hendriks
SMSabrina M. L. Moro
Sabrina M. L. Moro
EEEwa Ellis
Ewa Ellis
JWJoanne Walsh
Joanne Walsh
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
Liver biology and function, drug-induced liver injury (DILI) and liver diseases are difficult to study using current in vitro models such as primary human hepatocyte (PHH) monolayer cultures, as their rapid de-differentiation restricts their usefulness substantially. Thus, we have developed and extensively characterized an easily scalable 3D PHH spheroid system in chemically-defined, serum-free conditions. Using whole proteome analyses, we found that PHH spheroids cultured this way were similar to the liver in vivo and even retained their inter-individual variability. Furthermore, PHH spheroids remained phenotypically stable and retained morphology, viability and hepatocyte-specific functions for culture periods of at least 5 weeks. We show that under chronic exposure, the sensitivity of the hepatocytes drastically increased and toxicity of a set of hepatotoxins was detected at clinically relevant concentrations. An interesting example was the chronic toxicity of fialuridine for which hepatotoxicity was mimicked after repeated-dosing in the PHH spheroid model, not possible to detect using previous in vitro systems. Additionally, we provide proof-of-principle that PHH spheroids can reflect liver pathologies such as cholestasis, steatosis and viral hepatitis. Combined, our results demonstrate that the PHH spheroid system presented here constitutes a versatile and promising in vitro system to study liver function, liver diseases, drug targets and long-term DILI.

1 March 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
HBHesham Basma
Hesham Basma
ASAlejandro Soto–Gutiérrez
Alejandro Soto–Gutiérrez
GYGovardhana Rao Yannam
Govardhana Rao Yannam
LLLiping Liu
Liping Liu
RIRyotaro Ito
Ryotaro Ito
IFIra J. Fox
Ira J. Fox

15 March 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NMNicole Marquardt
Nicole Marquardt
Vivien BéziatVivien Béziat
Vivien Béziat
SNSanna Nyström
Sanna Nyström
JHJulia Hengst
Julia Hengst
MIMartin A Ivarsson
Martin A Ivarsson
NBNiklas Björkström
Niklas Björkström
Although NK cells are considered innate, recent studies in mice revealed the existence of a unique lineage of hepatic CD49a+DX5− NK cells with adaptive-like features. Development of this NK cell lineage is, in contrast to conventional NK cells, dependent on T-bet but not Eomes. In this study, we describe the identification of a T-bet+Eomes−CD49a+ NK cell subset readily detectable in the human liver, but not in afferent or efferent hepatic venous or peripheral blood. Human intrahepatic CD49a+ NK cells express killer cell Ig-like receptor and NKG2C, indicative of having undergone clonal-like expansion, are CD56bright, and express low levels of CD16, CD57, and perforin. After stimulation, CD49a+ NK cells express high levels of inflammatory cytokines but degranulate poorly. CD49a+ NK cells retain their phenotype after expansion in long-term in vitro cultures. These results demonstrate the presence of a likely human counterpart of mouse intrahepatic NK cells with adaptive-like features.

1 January 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
AOAdedamola Olayanju
Adedamola Olayanju
ICIan M. Copple
Ian M. Copple
HBHolly K. Bryan
Holly K. Bryan
GEGeorge T. Edge
George T. Edge
RSRowena L. Sison
Rowena L. Sison
BPB. Kevin Park
B. Kevin Park
The transcription factor Nrf2 regulates the basal and inducible expression of a battery of cytoprotective genes. Whereas numerous Nrf2-inducing small molecules have been reported, very few chemical inhibitors of Nrf2 have been identified to date. The quassinoid brusatol has recently been shown to inhibit Nrf2 and ameliorate chemoresistance in vitro and in vivo. Here, we show that brusatol provokes a rapid and transient depletion of Nrf2 protein, through a posttranscriptional mechanism, in mouse Hepa-1c1c7 hepatoma cells. Importantly, brusatol also inhibits Nrf2 in freshly isolated primary human hepatocytes. In keeping with its ability to inhibit Nrf2 signaling, brusatol sensitizes Hepa-1c1c7 cells to chemical stress provoked by 2,4-dinitrochlorobenzene, iodoacetamide, and N-acetyl-p-benzoquinone imine, the hepatotoxic metabolite of acetaminophen. The inhibitory effect of brusatol toward Nrf2 is shown to be independent of its repressor Keap1, the proteasomal and autophagic protein degradation systems, and protein kinase signaling pathways that are known to modulate Nrf2 activity, implying the involvement of a novel means of Nrf2 regulation. These findings substantiate brusatol as a useful experimental tool for the inhibition of Nrf2 signaling and highlight the potential for therapeutic inhibition of Nrf2 to alter the risk of adverse events by reducing the capacity of nontarget cells to buffer against chemical and oxidative insults. These data will inform a rational assessment of the risk:benefit ratio of inhibiting Nrf2 in relevant therapeutic contexts, which is essential if compounds such as brusatol are to be developed into efficacious and safe drugs.